Funding Structure, page-144

Correct Thaliat. Guidance is the path.
There seems to be some common misguided comments around an understanding of the CTAP process, prodominantly from posters who don't hold the stock.
Some due diligence in understanding the FDA's CTAP process, including funding, will assist their credibility.
Biotron announced in March and again in May, they are looking for a partner to assist with funding once they received guidance from FDA to progress BIT 225 through the CTAP process.

It was exciting to hear MM say in the March Monsoon presentation that the Scripp's researchers hadn't seen results as good as BIT 225 for a covid treatment and will be extremely difficult to understand why BIT225 wouldn't be attractive to a potential partner.
I am expecting news shortly on funding as Biotron have had these test results in hand for some time now, waiting for FDA guidance.
GLTAH